TR study of "A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (BIGBANG study)"

TR study of "A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (BIGBANG study)" - BIGBANG TR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031860

Enrollment

Registered

2018-04-01

Start date

2018-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients enrolled in BIGBANG study 2.Written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Cancer related genome analysis, gene expression and molecular characterization analysis	—

Countries

Japan

Contacts

Public ContactDaisuke Kotani

National Cancer Center Hospital East Department of Gastrointestinal Oncology

BIGBANG_core@east.ncc.go.jp0471331111

Outcome results